연구동향 분석
박사

Development of Cyclohexenone Derivatives as HDAC6-selective Inhibitors for the Treatment of Rheumatoid Arthritis

이창식 2016년

논문상세정보
인용/피인용
' Development of Cyclohexenone Derivatives as HDAC6-selective Inhibitors for the Treatment of Rheumatoid Arthritis' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Cyclohexenone
  • HDAC6
  • Rheumatoid Arthritis
  • ctla-4
  • tnfα
  • treg
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
188 0

0.0%

' Development of Cyclohexenone Derivatives as HDAC6-selective Inhibitors for the Treatment of Rheumatoid Arthritis' 의 참고문헌

  • d’Ydewalle, et al. (2011) HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nature Medicine 17(8): 968-975
  • de Zoeten, et al. (2011) Histone deacetylase 6 and heat shock protein 90 control the function of FoxP3+ T-regulatory cells. Mol Cell Boil. 31:2066-2078.
  • Yingxiu Li, (2013) Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. The FEBS journal 280 (3), 775
  • Yan, et al. (2014) HDAC6 Deacetylase Activity Is Critical for Lipopolysaccharide-Induced Activation of Macrophage. Public Library of Science One 9(10):1-8
  • Wing, et al. (2008) CTLA-4 Control over Foxp3+ Regulatory T cell Function. Science 322:271-274
  • Wang, et al. (2009) Immunomodulatory effects of deacetylase inhibitors : therapeutic target of FOXP3+ regulatory T cells. Nature Rev. 8; 969-981
  • Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376 (9746) : 1094-108
  • Santo, et al. (2011) Preclinical activity, pharmacodynamics and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 10:387365.
  • Ruijter, et al. (2003) Histone deacetylase (HDACs) : Chacterization of the classical HDAC family. Biochem. J. 370:737-749
  • Odagiri, et al. (2013) Brain expression level and activity of HDAC6 protein in neurodegenerative dementia. Biochemical and Biophysical Research Communications 430:394-399
  • Ocio, et al. (2010) In vitro and in vivo rationale for the triple combination of panobinostat (LBH-589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematol. 95, 5:794-803.
  • Novel Potent Inducer of Terminal Differentation and methods of Use Thereof. WO09307148
  • Novartis AG, Hydroxamate derivatives usefule as deacetylase inhibitors. WO02/022577.
  • Millecamps, et al. (2013) Axonal transport deficient and neurondegenerative disease. Nature Review Neuroscience Mar:14(3):161-176
  • Marks, et al. (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 13:477-483.
  • Marks, et al. (2001) Histone deacetylase and cancer : cause and therapies. Nat Rev Cancer. 1:194-202.
  • Majithia V, Geraci SA (2007) Rheumatoid Arthritis : Diagnosis and management. Am. J. Med. 120 (11) : 936-9
  • Maiso, et al. (2006) The histone deacetylase inhibitor LBH-589 is a potent antimyeloma agent that overcome drug resistance. Cancer Res. 66, 11:5781-5789.
  • Littell, Piperidinomethylene dihydrocarbazolones. US3740404.
  • Li, et al. (2013) Looped host defense peptide CLP-19 binds to microtubules and inhibits surface expression of TLR4 on mouse. J Immunol. 190:6083-6092.
  • Kozikowski, HDAC inhibitors and therapeutic methods the same. WO2011/011186.
  • Kekatpure, et al. (2009) HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J. Biol. Chem. 284:7436-7445
  • Johnstone, et al. (2002) Histone deacetylase inhibitors : novel drugs for the treatment of cancer. Nat Rev Drug Discov. 1:287-289.
  • Into, et al. (2010) Regulation of MyD88 aggregation and the MyD88 dependent signaling pathway by sequestosome 1 and histone deacetylase 6. J Biol Chem. 285:35759-35769.
  • Hubbert, et al. (2002) HDAC6 is a microtubule-associated deacetylase. Nature, 417:455-458
  • Handout on Health : Rheumatoid Arthritis. National Institute of Arthritis and Musculoskeletal and skin Disease. August 2014. Retrieved july 2, 2015
  • Gregoretti, et al. (2004) Molecular evolution of the histone deacetylase family : Functional implications of phylogenetic analysis. J. Mol. Biol. 338:17-31
  • Glaxo group limited, Process for preparing N-heterocyclic compounds. US4957609.
  • Fablan Flores-Boja, et al. (2008) Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 105:19396-19401
  • Emanuele, et al. (2008) Histone deacetylase inhibitors : apoptotic effects and clinical implications (Review). International Journal of Oncology. 33:637-646.
  • Dokmanovic, et al. (2007) Histone deacetylase inhibitor : overview and perspectives. Mol Cancer Res. 5, 10:981-989.
  • David M. Balch, of Coronado, California. US771760.
  • Datamonitor Healthcare (2016) 19th May, Rheumatoid Arthritis Disease Coverage
  • Butler, et al. (2010) Rational design and sample chemistry field a superior, neuroprotective HDAC6 inhibitor, Tubastatin A. J Am Chem Soc. 11, 132(31):10842-10846.
  • Buckner, (2010) Mechanism of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune disease. 10:849-859
  • Brown, Substituted 7-heterocyclic-7,8-dihydro-6-(hydroxyl or methoxy)-6,14-endo(etheno or ethano)codides and morphides. US3634430.
  • Boyault, et al. HDAC6, at the crossroads cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 26:5468-5476
  • Beier, et al. (2012) Histone deacetylase 6 and 9 and sirtuin-1 control FoxP3+ regulatory T cell function through shared and isotype-specific mechanisms. Sci Signal. 5, ra45.
  • Barta, et al. (2008) Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitor of HSP90. Bioorg Med Chem Lett. 18:3517-3521.
  • Acetylon pharmaceuticals, Reverse amide compounds as protein deacetylase inhibitors of use thereof. WO2011/091213.